A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease

Exclusion Criteria

• •A clinically significant disease other than Gaucher disease, severe complications from Gaucher disease, or serious intercurrent illness that precluded participation in the study in the opinion of the investigator
• •During the screening period, had any clinically significant findings as deemed by the investigator
• •Partial or total splenectomy
• •Documentation of moderate or severe pulmonary hypertension, defined as pulmonary arterial pressure \>35 millimeters of mercury (mmHg) or significant Gaucher-related lung disease
• •History of allergy or sensitivity to the study drug or any excipients, including any prior serious allergic reaction to iminosugars
• •Pacemaker or other contraindication for magnetic resonance imaging (MRI) scanning
• •Pregnant or breast-feeding
• •Current/recent drug or alcohol abuse
• •Treatment with any investigational product in the last 90 days before study entry
• •Treatment in the previous 90 days with any drug known to have a well-defined potential for toxicity to a major organ
• •Presence of symptoms of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs